ObsEva S.A. (OBSEF)
OTC PINK OTC PINK Primary Summary
ObsEva S.A. (OBSEF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ObsEva S.A. ever had a stock split?
ObsEva S.A. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Ernest Loumaye M.D., OB/GYN, Ph.D. CEO | OTC PINK Exchange | CH1260041939 ISIN |
| US Country | 15 Employees | - Last Dividend | 6 Dec 2016 Last Split | - IPO Date |
Overview
ObsEva SA is a pioneering biopharmaceutical entity, centered on ushering in revolutionary therapeutic solutions aimed at bolstering women's reproductive health. Established in 2012, and with its headquarters nestled in Geneva, Switzerland, this visionary company strides toward harnessing the potential of novel scientific discoveries to offer better clinical outcomes for women worldwide. ObsEva SA dedicates itself tirelessly to the exploration and development of innovative treatments that address the intricate necessities of reproductive health, marking its authority in the biopharmaceutical domain through relentless pursuit of excellence and innovation.
Products and Services
Nolasiban: At the heart of ObsEva SA's product portfolio is Nolasiban, a groundbreaking oral oxytocin receptor agonist crafted with precision to amplify clinical pregnancy and live birth rates among women undergoing in-vitro fertilization (IVF) treatments. This therapeutic offering stands as a testament to ObsEva's commitment to transforming the landscape of reproductive healthcare through scientific innovation. By targeting the oxytocin receptor, Nolasiban aims to enhance uterine receptivity, thereby increasing the odds of successful implantation and pregnancy in IVF procedures.
